2022 Conference Publication Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890800.36906.bb |
2022 Conference Publication Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin LymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17 |
2022 Conference Publication Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 studyJohnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
2022 Conference Publication Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 studyTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Inna, Tzoran, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
2021 Conference Publication Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD StudyManos, Kate, Khor, Richard, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew M., Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Hawkes, Eliza (2021). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. |
2020 Conference Publication Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphomaTsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954 |
2020 Conference Publication Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD studyHawkes, Eliza Anne, Manos, Kate, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael Patrick, Keane, Colm, Scott, Andrew Mark, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison Anne, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2020). Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, May 29-31, 2020. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
2019 Conference Publication Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockadeNath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050 |
2019 Conference Publication y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD StudyHawkes, Eliza A., Manos, Kate, Chong, Geoff, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze-Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2019). y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL USA, 7-10 December 2019. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2019-122635 |
2019 Conference Publication EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapyGandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629 |
2019 Conference Publication B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCLGould, Clare, Keane, Colm, Murigneux, Valentine, Oey, Harald, Ellis, Jonathan, Birch, Simone, Gunawardana, Jay, Talaulikar, Dipti, Hertzberg, Mark S., Jones, Kimberley and Gandhi, Maher K. (2019). B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL. ASH Annual Meeting, Orlando, FL, United States, 7-10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-126537 |
2018 Conference Publication A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trialAbro, Emad Uddin, Law, Soi C., Keane, Colm, Birch, Simone, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Johnson, Peter, Trotman, Judith, Berkahn, Leanne, Fulham, Michael, Anderson, Richard A., Saunderson, Anne L., Gunawardana, Jay, Cross, Donna, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Law, W. P., Gill, Devinder and Gandhi, Maher K. (2018). A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial. 60th ASH Annual Meeting, San Diego, CA United States, 1-4 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-112008 |
2018 Conference Publication The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular LymphomaTobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826 |
2018 Conference Publication The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin LymphomaGunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836 |
2018 Conference Publication Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor PrognosisKeane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830 |
2017 Conference Publication The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphomaTobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh , Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728 |
2017 Conference Publication The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical TrialShanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
2017 Conference Publication The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLDGandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology. |
2017 Conference Publication The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic LeukaemiaTobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
2016 Conference Publication A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell LymphomaGandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology. |